Biomoda Honors Veterans with Pledge to Lower Rate of Lung Cancer
|
| Posted
:
Mon, 09 Nov 2009 18:24:43 GMT |
| Author
:
Biomoda, Inc.
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
ALBUQUERQUE, N.M. - (Business Wire) Biomoda, Inc. (OTCBB: BMOD) President John Cousins called upon governors in all 50 states to proclaim November “Lung Cancer Awareness Month” on behalf of veterans and their families and pledged to continue the company’s focus on veterans in the research, development and commercialization of diagnostic technology for detection of early-stage lung cancer. “America can truly honor its 25 million veterans by making a commitment to fight lung cancer. Veterans have a 25 percent higher risk than the general population of developing lung cancer and dying from the disease,” Cousins said. “The men and women who served our country deserve nationwide recognition that lung cancer is a significant threat to their health, and they deserve our commitment to lower their risk with early detection and awareness.” Based on a molecular marker technology originally developed at Los Alamos National Laboratory, Biomoda’s CyPath® assay is expected to improve the survivability of lung cancer through early detection and treatment. “As we prepare to expand our clinical trial to multiple sites across the country, we will continue to focus research on lowering the cancer burden carried by veterans, and we urge others to do the same,” Cousins said. Cousins called upon the nation’s governors to issue proclamations declaring November “Lung Cancer Awareness Month” on Veterans Day. He applauded The Lung Cancer Alliance and its nationwide campaign to obtain proclamations from all 50 states. “The Lung Cancer Alliance continues its service to our veterans by providing the means for every governor to join in the fight and issue a proclamation that highlights the dismal statistics our veterans face and gives hope that those statistics soon will change for the better.” Biomoda’s first product, an in-vitro test for the detection of early-stage lung cancer, is currently in Phase II clinical trials. Study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay in the Biomoda lab. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm accuracy. Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Biomoda, Inc. John Cousins, 505-821-0875
|

Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
SEATTLE, Nov. 24 -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 21st Annual Piper Jaffray Health Care Conference. The conference will be held December 1-2, 2009, at the New York Palace Hotel.
CTI will present on...
Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent CP-4126 OSLO, NORWAY and BOULDER, CO -- 11/24/09 --
* CP-4126 is a novel, lipid-conjugated form of gemcitabine designed
by Clavis Pharma to improve treatment outcomes in patients with
pancreatic and other solid tumours
* Clavis..
Option 3G solution in Google Android 2.0 development platform for pocket, handheld and tablet devices from MOTO Development Group LEUVEN, BELGIUM -- 11/24/09 --
Option, the wireless technology
company, today announced that its GTM501, the world's smallest 3G
module and one of Option's broadband wireless breakthroughs, will be
used in MOTO Development Grou..
Telenet Upgrades to Acision's Next Generation Messaging Platform With Latest Voice Messaging Services
READING, England, November 24 /PRNewswire/ --
- Next Generation Messaging Architecture to Support Advanced Voice
Messaging and Future Unified Communication Applications
Acision, the world's leading messaging company, today announce...
Dassault Systèmes Helps French Pavilion Become First World Expo Participant to Launch True Interactive 3D Pavilion SHANGHAI -
Dassault Systèmes (DS) (Paris:DSY) (Euronext Paris: #13065, DSY.PA), a
world leader in 3D and Product Lifecycle Management (PLM) solutions, and
the French Pavilion at the Shanghai World Expo 2010 today unveiled the
first true, interactive, 3D virtual pavilion among particip
Customer Satisfaction Drops: Results for Banks, Mortgage Lenders, Credit Cards and Insurance LONDON -
The National Customer Satisfaction Index (NCSI-UK) drops slightly
for a second straight quarter, now 72.8 on a 100-point scale. The
decline is a result of an overall loss of customer satisfaction in the
financial services sector.
Gas Natural Adopts SmartSignal Predictive Diagnostics Fleet-Wide LISLE, Ill. -
SmartSignal® Corporation today announced that Gas Natural has
selected SmartSignal EPI*Center® software to monitor 22
combined cycle units and six coal power units, responsible for 10,774 MW
of power generation, across Spain and Mexico. In 2010, EP
|
|
|
|
|
|
|
|
|